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Number of Target Lesions for EASL and Modiﬁed RECIST to
Predict Survivals in Hepatocellular Carcinoma Treated with
Chemoembolization
Beom Kyung Kim1,4, Seung Up Kim1,3,4, Myeong-Jin Kim2, Kyung Ah Kim2, Do Young Kim1,3,4,
Jun Yong Park1,3,4, Sang Hoon Ahn1,3,4,5, Kwang-Hyub Han1,3,4,5, and Chae Yoon Chon1,3,4
Abstract
Purposes: To date, most studies about the optimal number of target lesions for enhancement criteria for
hepatocellular carcinoma (HCC) have focused on cross-sectional analyses of concordance. We investigated
the optimal number of target lesions for European Association for the Study of the Liver (EASL) andmodified
Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS).
Experimental Design:We analyzed 254 consecutive treatment-na€ve patients with HCC having at least
2 measurable target lesions undergoing transarterial chemoembolization. Kappa values for intermethod
agreement of treatment responses were calculated for comparisons between use ofmaximumof 1, 2, 3, 4, or
5 targets versus use of all target lesions. Prognostic values of radiologic assessments according to number of
target lesions for predicting OS were expressed as C-index.
Results: By EASL and mRECIST guidelines, k values between responses assessing the longest 2, 3, 4, or 5
targets and assessing all targets were 0.924, 0.977, 1.000, or 1.000 and 0.907, 0.959, 1.000, or 1.000,
respectively, whereas those between responses assessing only one target and assessing all target lesions were
0.723 and 0.666, respectively. C-index when measuring the longest 1, 2, 3, 4, 5, and all targets was similar,
ranging from 0.739 to 0.749 for EASL criteria and from 0.750 to 0.759 for mRECIST. From Cox regression
analyses, radiologic response fromeach calculationmethod showed independently significant effects onOS
for both guidelines, regardless of number of target lesions.
Conclusions: Prognostic values for predicting OS were similar regardless of number of target lesions.
Assessing the 2 largest targets rather than only 1 index lesion could be recommended considering high
concordances from cross-sectional analyses. Clin Cancer Res; 19(6); 1503–11. 2012 AACR.
Introduction
World Health Organization (WHO) and Response Eval-
uation Criteria in Solid Tumors (RECIST) guidelines have
been universally accepted to evaluate treatment responses
of solid tumors (1, 2). However, these 2 conventional size-
based criteria designed primarily for evaluation of cytotoxic
agents do not address measures of antitumor activity other
than tumor shrinkage (2). In particular, for hepatocellular
carcinoma (HCC), recent studies have shown poor correla-
tions between conventional methods of response evalua-
tion and clinical benefits provided by molecular-targeted
agents, transarterial chemoembolization (TACE), or other
local ablative therapy, as these criteria generally ignore
tumor necrosis or decreased tumor viability induced from
such treatments (3–5). Furthermore, because regenerative
nodules can appear as new lesions and tumors do not
change in appearance on imaging due to preexisting fibrous
matrix despite successful treatment, sized-based criteria
leave much to be desired.
Therefore, theHCCpanel of the EuropeanAssociation for
the Study of the Liver (EASL) established consensus criteria
in 2001, called EASL criteria, in which arterially enhanced
tumor burden indicating the remaining viable tumor after
treatment is calculated bidimensionally (6). Thereafter, a
complementary framework to assess therapeutic response
was formally introduced in 2008 based on guidelines estab-
lished by the American Association for the Study of Liver
Diseases—Journal of the National Cancer Institute (7). The
revised guidelines, called modified RECIST (mRECIST;
ref. 5), consider both concept of tumor viability based on
arterial enhancement (i.e., from EASL criteria) and single
linear summation (i.e., fromRECIST; refs. 5, 7). In addition,
mRECIST is a major step forward compared with the
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previous enhancement method, EASL criteria, in terms that
mRECIST not only somewhat simplifies complex EASL
criteria, but also provides special recommendations for new
lesion and nontarget lesions, such as portal vein thrombo-
sis, lymph node at porta hepatis, ascites, or pleural effusion
in detail. EASL and mRECIST guideline have shown super-
ior efficacy for assessing treatment responses and predicting
survival outcomes comparedwithWHOand RECIST guide-
lines in patients with HCC because enhancement criteria
can discriminate patients with better clinical outcomes by
tumor necrosis, regardless of shrinkage of entire tumormass
(3, 8–12).
Meanwhile,Warr and colleagues (13) showed that at least
2 or 3 index lesions should be measured to minimize false
categorization of the final response for WHO criteria. And,
the current RECIST criteria are designed to assess a maxi-
mum of 2 measurable target lesions per organ that are
representative of all lesions within each organ (14). How-
ever, in contrast to size criteria, when using enhancement
criteria, the least number of target lesions that should be
measured to achieve an equal predictive value for long-term
survival outcomes remains uncertain compared with what
would be achieved if all lesions were considered. In partic-
ular, clinical outcomes about overall survival (OS), the
robust and unequivocal endpoint for clinical trials, accord-
ing to maximum number of target lesions have never been
analyzed for enhancement criteria.
Here, we aimed to determine the optimal number of
target lesions for EASL and mRECIST guidelines from per-
spectives of predicting survival outcomes among treatment-
na€ve patients with HCC undergoing TACE.
Materials and Methods
Patient eligibility
Through the retrospective review from the prospectively
registered data bank fromYonsei LiverCancer Special Clinic
(Seoul, Republic of Korea), treatment-na€ve patients with
multifocal intrahepatic HCCwho received first-line therapy
with TACE between June 2006 and December 2009 were
eligible for this study. On recruitment, exclusion criteria
were as follows: presence of a solitary target lesion, inad-
equate target lesion (i.e., infiltrative pattern or largest lesion
less than 1 cm), presence of an additional primary malig-
nancy in another organ, presence of extrahepatic lesions or
vascular invasion, Child–Pugh class B or C, and presence of
uncontrolled functional or metabolic disease (Supplemen-
tary Fig. S1).
This studyprotocolwas conducted in accordancewith the
ethical guidelines of the 1975 Declaration of Helsinki, and
written informed consent was obtained from each partic-
ipant or responsible family member. This study procedure
was approved by the Institutional Review Board of Sever-
ance Hospital, Yonsei University College of Medicine
(Seoul, Republic of Korea).
Diagnosis of HCC
Diagnosis of HCC and assessment of treatment response
were conducted with a dynamic imaging study involving 4
phases (precontrast, arterial, portal, and equilibrium
phases) using contrast-enhanced computed tomography
(CT) or gadolinium-enhanced MRI as appropriate (5,
6, 14). Diagnosis of HCC was made based on guidelines
proposed by Korea Liver Cancer Study Group (15). Accord-
ing to these criteria, a patient is considered positive forHCC
if they have 1 or more risk factors (hepatitis B or C virus
infection, cirrhosis) and one of the following: seruma-feto-
protein (AFP) more than 400 ng/mL and a positive finding
on at least 1 of 3 typical imaging studies (dynamic CT,
dynamicMRI, or hepatic angiography), or serumAFP of less
than 400 ng/mL and positive findings on at least 2 of 3
imaging studies. A positive finding for typical HCC on
dynamic CT or MRI was defined as increased arterial
enhancement followed by decreased enhancement com-
pared with liver (washout) in the portal or equilibrium
phase.
Treatment modality
TACE was conducted by infusion with a mixture of 5 mL
iodized oil contrast medium (lipiodol; Guerbet) and 50mg
adriamycin (Ildong Pharmaceutical) followed by emboli-
zation of feeding arteries using gelatin sponge particles
(Cutanplast; Mascia Bruneili S.p.A.). Sequential TACE was
scheduled at 6- to 8-week intervals when a residual viable
tumor was detected in liver on a follow-up assessment
without appearance of extrahepatic metastases, major por-
tal vein invasion, or deterioration in clinical status or
laboratory values.
Assessment of treatment responses using EASL and
mRECIST guidelines
Both guidelines define viable tumors according to uptake
of contrast material in the arterial phase of dynamic CT or
MRI; tumors retaining iodized oil and necrotic lesions
without intratumoral arterial enhancement were regarded
Translational Relevance
Regarding European Association for the Study of the
Liver (EASL) and modified Response Evaluation Criteria
in Solid Tumors (mRECIST) guidelines for hepatocellular
carcinoma (HCC), the least number of target lesions that
should be measured to achieve an equal predictive value
for long-term survival outcomes remains uncertain. The
most ideal approach is to consider all target lesions;
however, it requires much unnecessary time and labor.
By EASL and mRECIST guidelines, C-index, which was
calculated to evaluate prognostic values of each radio-
logic method according to number of target lesions
(assessing the longest 1, 2, 3, 4, 5, and all targets) for
predicting overall survival (OS), was similar, ranging
from 0.739 to 0.749 for EASL criteria and from 0.750 to
0.759 for mRECIST, regardless of number of target
lesions. In conclusion, prognostic values for predicting
OS were similar regardless of number of target lesions.
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as necrotized tumor foci. Treatment responseswere assessed
4 weeks after the initial TACE using both guidelines. EASL
criteria are based on product of bidimensional diameters of
enhanced area ofmeasurable lesions, whereasmRECIST are
based on sum of unidimensional measurements. All target
lesions must be at least 10 mm in diameter and distinctly
nodular (5).
Tumor response was quantitatively defined as complete
response (CR), as indicated by complete disappearance of
measurable lesions for both guidelines, or partial response
(PR), defined as a 50% decrease from baseline for EASL
criteria and a 30% decrease from baseline for mRECIST.
Progressive disease was defined by a 25% increase from
baseline for EASL criteria and a 20% increase from baseline
for mRECIST. Stable disease was defined as a value between
progressive disease and PR. Objective response rate referred
to sum of CR and PR.
In per-patient agreement analysis, a response for a
given patient based on all measurable lesions was com-
puted and used as reference to further investigate poten-
tial outcome differences between assessment of 1, 2, 3, 4,
or 5 target lesions. Target lesions were selected in order of
their maximum diameter at baseline so as to be presum-
ably representative of entire tumor burden: the longest 1,
2, 3, 4, and 5 lesions. Lesions other than designated target
lesions for each methodology, always including any small
lesions with a maximum diameter of less than 10 mm and
truly nonmeasurable lesions, were considered as nontar-
get lesions.
For both guidelines, target responses take into account
changes in only designated target lesions, whereas overall
responses comprehensively take into consideration changes
in target lesions, nontarget lesions, and appearance of
intrahepatic or extrahepatic new lesions. The overall
response status according to possible combinations of
response classes in target and nontarget lesions with or
without appearance of new lesions is shown in Table 1.
Radiologic responses were interpreted by both assess-
ments protocols (EASL and mRECIST guideline) for the
same target lesions on the same scan at the same time. To
minimize possibility of false categorizations, all mea-
surements were conducted by 2 independent observers
(K.A. Kim and M.-J. Kim with 10 and 30 years of expe-
rience, respectively), both blinded to clinical data. Then,
ultimately, final classifications made by consensus
between 2 observers were adopted for analysis. Detailed
data on agreement are provided in the Supplementary
Table S1.
Statistical analysis
First, we examined intraindividual agreement rates,
which was defined as the percentage of patients with the
same result between response status, when considering only
the longest 1, 2, 3, 4, or 5 lesions compared with all
measurable lesions among whole population. Concor-
dance between response assessments based on all measur-
able lesions in a given patient versus the longest 1, 2, 3, 4, or
5 lesions in the same patient was estimated using k values.
The strength of concordance based on k values was inter-
preted as follows: k < 0.21, poor; k 0.21–0.40, fair; k 0.41–
0.60, moderate; k 0.61–0.80, good; and k > 0.80, excellent
(16).
Next, we investigated prognostic values of treatment
responses about OS, the primary endpoints of this study,
when considering only the longest 1, 2, 3, 4, 5, and all
target lesions, using EASL and mRECIST guidelines,
respectively. Each prognostic value for OS was expressed
as C-index, which was a natural extension of area under
the receiver operating characteristic curve to analyze sur-
vival outcomes observed during longitudinal follow-up as
a means of assessing discrimination with competing
models (17).
OS was calculated as time interval between date of ini-
tiation of TACE and date of death or last follow-up, whereas
progression-free survival (PFS) was calculated as time inter-
val between date of initiation of TACE and date of progres-
sion or death. Survival timewas estimated by Kaplan–Meier
method, and survival difference between groups was
assessed by log-rank test. For patients who underwent
resection or liver transplantation after TACE, survival was
censored at the time of surgery. Cox proportional HRs were
calculated to test associations of clinical parameters with
survivals.
Statistical analysis was conducted using SAS software
version 9.1.3 (SAS Institute), and a 2-sided P value of less
than 0.05 was considered statistically significant.
Table 1. Overall responses determined by evaluation of target, nontarget, and new lesions
Target lesions Nontarget lesions New lesions Overall response
CR CR Absent CR
CR Non-CR or nonprogressive disease Absent PR
CR Unmeasurable Absent PR
PR Nonprogressive disease or unmeasurable Absent PR
Stable disease Nonprogressive disease or unmeasurable Absent Stable disease
Progressive disease Any response Present or absent Progressive disease
Any response Progressive disease Present or absent Progressive disease
Any response Any response Present Progressive disease
Optimal Number of Target Lesions for mRECIST and EASL
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Results
Baseline characteristics
Baseline demographic and clinical characteristics are
shown in Table 2. The median age of population (199 men
and 55 women) was 60 (range, 34–75) years. All had
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 or 1 and preserved liver function of
Child–Pugh class A. The median diameter of the largest
measurable lesionwas 3.1 (range, 1.5–9.7) cm. The number
of baseline measurable lesions was 2 in 128 patients
(50.4%), 3 in 53 patients (20.9%), 4 in 40 (15.7%), and
5 ormore in 33 (13.0%) patients. Themedian AFP level was
78.0 (range, 0.88–107,900) ng/mL.
Intraindividual agreement rates
Treatment responses according to EASL criteria are
described in Table 3 (cells with agreement are in gray). In
per-patient analysis, estimating amaximumnumber of 2, 3,
4, or 5 target lesions chosen in order of size resulted in an
agreement rate of 95.3%, 98.4%, 100%, or 100% for target
response and 94.9%, 98.4%, 100%, or 100% for overall
response, respectively, compared with response estimating
all measurable target lesions (Supplementary Fig. S2A and
S2B). These results were significantly higher compared with
agreement rates of 80.7% and 81.1% for target and overall
response, respectively, obtained when considering only the
Table 2. Patients' baseline characteristics
(n ¼ 254)
Variables Values
Age, y 60 (34–75)
Male gender 199 (78.3%)
Etiology
HBV 161 (63.4%)
HCV 40 (15.7%)
Alcohol 30 (11.8%)
Others 23 (9.1%)
ECOG performance status
0/1 163 (64.2%)/91 (35.8%)
Tumor number
2 128 (50.4%)
3 53 (20.9%)
4 40 (15.7%)
5 33 (13.0%)
Tumor size, cm 3.1 (1.5–9.7)
MELD score 4.98 (1–15.55)
AFP, ng/mL 78.0 (0.88–107,900)
NOTE: Values are expressed as median (range) or no. (%),
unless indicated otherwise.
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus.
Table 3. Detailed responses according to maximum number of target lesions using EASL and mRECIST
guideline
EASL criteria mRECIST
Target responses Overall responses Target responses Overall responses
All targets All targets All targets All targets
Maximum number
of targets CR PR
Stable
disease
Progressive
disease CR PR
Stable
disease
Progressive
disease CR PR
Stable
disease
Progressive
disease CR PR
Stable
disease
Progressive
disease
Up to 1 CR 93 31 1 0 90 31 1 0 93 31 1 0 90 31 1 0
PR 0 59 6 0 0 59 6 0 0 48 8 1 0 48 8 1
Stable disease 0 9 50 0 0 9 46 0 0 15 55 0 0 15 50 0
Progressive disease 0 0 2 3 0 0 1 11 0 0 2 0 0 0 2 8
Up to 2 CR 93 4 0 0 90 5 0 0 93 4 0 0 90 4 0 0
PR 0 91 2 0 0 90 2 0 0 83 3 0 0 83 3 0
Stable disease 0 4 56 1 0 4 51 1 0 7 62 1 0 7 57 1
Progressive disease 0 0 1 2 0 0 1 10 0 0 1 0 0 0 1 8
Up to 3 CR 93 2 0 0 90 2 0 0 93 2 0 0 90 2 0 0
PR 0 96 0 0 0 96 0 0 0 89 1 0 0 89 1 0
Stable disease 0 1 59 1 0 1 54 1 0 3 65 1 0 3 60 1
Progressive disease 0 0 0 2 0 0 0 10 0 0 0 0 0 0 0 8
Up to 4 CR 93 0 0 0 90 0 0 0 93 0 0 0 90 0 0 0
PR 0 99 0 0 0 99 0 0 0 94 0 0 0 94 0 0
Stable disease 0 0 59 0 0 0 54 0 0 0 66 0 0 0 61 0
Progressive disease 0 0 0 3 0 0 0 11 0 0 0 1 0 0 0 9
Up to 5 CR 93 0 0 0 90 0 0 0 93 0 0 0 90 0 0 0
PR 0 99 0 0 0 99 0 0 0 94 0 0 0 94 0 0
Stable disease 0 0 59 0 0 0 54 0 0 0 66 0 0 0 61 0
Progressive disease 0 0 0 3 0 0 0 11 0 0 0 1 0 0 0 9
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1 largest lesion with reference to response estimating all
measurable targets (Supplementary Fig. S2A and S2B).
Treatment responses according tomRECIST are described
in Table 3 (cells with agreement are in gray). Similarly,
estimating a maximum number of 2, 3, 4, or 5 largest target
lesions resulted in an agreement rate of 93.7%, 97.2%,
100%, or 100% for target response and 93.7%, 97.2%,
100%,or 100% for overall response, respectively, compared
with response estimating all baseline measurable lesions
(Supplementary Fig. S2C and S2D). These results were
significantly higher compared with agreement rates of
77.2% and 77.2% for target and overall response, respec-
tively, obtained when considering only the 1 largest lesion
with reference to response estimating all measurable targets
(Supplementary Fig. S2C and S2D).
Concordance between response evaluation methods
Kappa statistics showed "excellent" concordances
between responses assessed using all measurable targets
and using 2, 3, 4, or 5 largest target lesions by EASL criteria,
as reflected by high k values of 0.929 [95% confidence
interval (CI), 0.889–0.968], 0.976 (95% CI, 0.953–
0.999), 1.000 (95% CI, 1.000–1.000), or 1.000 (95% CI,
1.000–1.000) for target response and 0.924 (95% CI,
0.885–0.964), 0.977 (95% CI, 0.954–0.999), 1.000 (95%
CI, 1.000–1.000), or 1.000 (95% CI, 1.000–1.000) for
overall response, respectively. However, k values between
responses assessed using only the 1 longest target lesion and
those using all measurable targets were 0.710 (95% CI,
0.639–0.781) and 0.723 (95% CI, 0.653–0.793) for target
and overall response, respectively, showing only "good"
levels of concordance.
Similarly, k values between responses assessed using all
measurable targets and using 2, 3, 4, or 5 largest target
lesions by mRECIST were 0.905 (95% CI, 0.860–0.950),
0.958 (95% CI, 0.928–0.989), 1.000 (95% CI, 1.000–
1.000), or 1.000 (95%CI, 1.000–1.000) for target response
and 0.907 (95% CI, 0.864–0.951), 0.959 (95% CI, 0.930–
0.989), 1.000 (95% CI, 1.000–1.000), or 1.000 (95% CI,
1.000–1.000) for overall response. Those between
responses assessed using only the 1 longest target lesion
and using all measurable targets were 0.657 (95% CI,
0.582–0.731) and 0.666 (95% CI, 0.593–0.739) for target
and overall response, respectively, showing only "good"
levels of concordance.
Prognostic value of mRECIST for predicting OS
compared with EASL criteria
We calculated C-index to show prognostic values of each
radiologic parameter in predicting OS. C-index by EASL
criteria whenmeasured using the longest 1, 2, 3, 4, 5, and all
target lesions was similar in both target responses, ranging
from 0.716 to 0.724 and overall responses ranged from
0.739 to 0.749 (Table 4).
Likewise, C-index bymRECIST whenmeasured using the
longest 1, 2, 3, 4, 5, and all target lesions was also similar in
both target responses, ranging from 0.724 to 0.733 and
overall responses ranged from 0.750 to 0.759 (Table 4).
Influence of radiologic response on OS
For target responses, using EASL and mRECIST guide-
lines, responders (subjects with CR and PR) had a signif-
icantly longer median OS than nonresponders (subjects
with stable disease and progressive disease), regardless of
maximum number of target lesions (Table 5). Likewise, for
overall responses, using both criteria, similar results were
obtained (Table 5). Figure 1 showed Kaplan–Meier analysis
of OS using EASL criteria (A) and mRECIST (B).
Detailed HRs for both criteria are depicted in the Sup-
plementary Table S2.
Table 4. Prognostic value for OS and PFS of EASL and mRECIST guidelines
C-index for OS C-index for PFS
Maximum number
of targets
Target responses
by EASL criteria
Overall responses
by EASL criteria
Target responses
by EASL criteria
Overall responses
by EASL criteria
Up to 1 0.716 0.739 0.711 0.710
Up to 2 0.718 0.744 0.709 0.723
Up to 3 0.719 0.744 0.707 0.724
Up to 4 0.724 0.749 0.711 0.728
Up to 5 0.724 0.749 0.711 0.728
All targets 0.724 0.749 0.711 0.728
Target responses
by mRECIST
Overall responses
by mRECIST
Target responses
by mRECIST
Overall responses
by mRECIST
Up to 1 0.726 0.750 0.702 0.718
Up to 2 0.733 0.759 0.717 0.724
Up to 3 0.729 0.755 0.719 0.726
Up to 4 0.724 0.750 0.712 0.729
Up to 5 0.724 0.750 0.712 0.729
All targets 0.724 0.750 0.712 0.729
Optimal Number of Target Lesions for mRECIST and EASL
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Other independent factors influencing OS
Clinical variables other than radiologic responses,
including age, sex, performance status, disease etiology,
AFP level, model for end-stage liver disease (MELD) score,
tumor number, and tumor size (largest lesion diameter)
were analyzed in univariate analysis forOS (Supplementary
Table S2). Among them, AFP level (P < 0.001), tumor
number (P < 0.001), and tumor size (P ¼ 0.047) were
significant predictors of OS. Thus, these 3 variables were
entered into a subsequent multivariate analysis along with
one of the following radiologic parameters: target and
overall responses by EASL criteria (responders vs. nonre-
sponders) and target and overall responses by mRECIST
(responders vs. nonresponders) when assessed by 1, 2, 3,
4, 5, and all target lesions, respectively. Each multivariate
analysis showed independent significance of radiologic
response from each calculation method (all P <
0.001; Table 5). Detailed adjusted HRs from multivariate
analysis are described in Table 5. Among remaining 3
clinical variables (AFP level, tumor size, and tumor num-
ber), AFP level and tumor number remained independent-
ly significant (both P < 0.05 in each multivariate analysis)
along with radiologic response from each calculation
method.
Table 5. Detailed median OS and adjusted HR from multivariate analysis
Target response by EASL criteria Overall responses by EASL criteria
Maximum number
of targets
OS, mo (responders vs.
nonresponders) Adjusted HRs (95% CI)
OS, mo (responders vs.
nonresponders) Adjusted HRs (95% CI)
Up to 1 40.5 vs. 20.7 2.079 (1.416–3.054) 40.8 vs. 20.7 2.270 (1.554–3.314)
Up to 2 40.5 vs. 21.2 1.765 (1.195–2.607) 40.8 vs. 21.2 1.937 (1.320–2.844)
Up to 3 40.5 vs. 21.2 1.733 (1.171–2.565) 40.8 vs. 20.7 1.904 (1.295–2.798)
Up to 4 40.5 vs. 21.2 1.733 (1.171–2.565) 40.8 vs. 21.2 1.904 (1.295–2.798)
Up to 5 40.5 vs. 21.2 1.733 (1.171–2.565) 40.8 vs. 21.2 1.904 (1.295–2.798)
All targets 40.5 vs. 21.2 1.733 (1.171–2.565) 40.8 vs. 21.2 1.904 (1.295–2.798)
Target responses by mRECIST Overall responses by mRECIST
OS, mo (responders vs.
nonresponders) Adjusted HRs (95% CI)
OS, mo (responders vs.
nonresponders) Adjusted HRs (95% CI)
Up to 1 40.8 vs. 25.3 2.287 (1.571–3.329) 40.8 vs. 22.9 2.491 (1.717–3.614)
Up to 2 40.8 vs. 21.3 2.108 (1.444–3.077) 40.8 vs. 21.2 2.303 (1.584–3.348)
Up to 3 40.8 vs. 21.3 2.243 (1.538–3.271) 40.8 vs. 21.2 2.447 (1.685–3.555)
Up to 4 40.8 vs. 23.3 2.163 (1.480–3.162) 40.8 vs. 21.3 2.363 (1.624–3.439)
Up to 5 40.8 vs. 23.3 2.163 (1.480–3.162) 40.8 vs. 21.3 2.363 (1.624–3.439)
All targets 40.8 vs. 23.3 2.163 (1.480–3.162) 40.8 vs. 21.3 2.363 (1.624–3.439)
NOTE:AdjustedHRswerecalculated, adjustingother3clinical variables, tumormarker, tumorsize, and tumornumber frommultivariate
analysis.
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Figure 1. Kaplan–Meier analysis of
OS using EASL criteria (A) and
mRECIST (B). Representatively,
overall treatment responses
considering up to 2 target lesions
were depicted, showing that
responders had a signiﬁcantly
longer median OS compared with
nonresponders (both P < 0.001).
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Radiologic responses and PFS
We also calculated C-index to show prognostic values of
each radiologic parameter in predicting PFS. Similar results
were obtained;C-index by EASL criteria andmRECISTwhen
measured using the longest 1, 2, 3, 4, 5, and all targets were
similar in both target and overall responses (Table 4).
Furthermore, responders had the independently better
PFS as compared with nonresponders; 10.1 (95% CI, 7.4–
12.5) versus 6.4 (95% CI, 5.3–7.6) months frommRECIST
and 10.1 (95% CI, 8.1–12.1) versus 6.6 (95% CI, 5.2–8.0)
months from EASL criteria (both P < 0.001), when overall
treatment responses considering up to 2 target lesions were
evaluated. Similar results were obtained for all radiologic
parameters; target and overall responses by EASL criteria
(responders vs. nonresponders) and target and overall
responses by mRECIST (responders vs. nonresponders)
when assessed by 1, 2, 3, 4, 5, and all targets, respectively.
Discussion
To date, although response evaluation criteria, such as
EASL andmRECIST, which take into consideration tumoral
devascularization and/or necrosis using arterial enhance-
ment of dynamic imaging get more popularity, investiga-
tions on optimum number of target lesions that should be
evaluated for appropriate representation of overall tumor
burden at baseline and subsequent follow-up are scarce. In
response analyses, use of specific numbers of measurable
targets shouldmeet 2major prerequisites: first, avoidance of
interobserver variability and measurement errors, and sec-
ond, avoidance of overburdening researchers with work in
real clinical practice (18, 19). Clinical outcomes based on
unoptimized target numbers can lead to misleading inter-
pretations and erroneous clinical applications of a given
treatment modality. Hence, we aimed to provide strong
evidence to support the choice of the optimal number of
target lesions that should be used in response evaluation
following TACE for HCC based on analysis of OS, the most
robust and unequivocal clinical parameter as a primary
endpoint.
In our study, intraindividual agreement rates in response
evaluation were similar when they were estimated using 2,
3, 4, or 5 targets chosen in order of size with reference to all
HCC lesions, ranging from about 94% to 100% for both
target and overall responses using EASL and mRECIST
guidelines. However, agreement rates using only the 1
largest lesion were significantly low, ranging from approx-
imately 77% to 81%. In a similar context, concordances
between responses assessedusing allmeasurable targets and
using 2, 3, 4, or 5 largest targets by EASL and mRECIST
guidelines were of "excellent" levels for both target and
overall responses, whereas estimation of only the longest 1
target lesion showed only a "good" level of concordance
with reference to responses using all measurable target
lesions. These findings were consistent with results by Shim
and colleagues (20), who indicated that evaluating the
largest 2 lesions is generally the most useful procedure for
assessing TACE responses under EASL and mRECIST guide-
lines. However, beyond above cross-sectional data, we took
a step forward. We showed that prognostic abilities for
predicting OS through a longitudinal study design, which
was expressed as C-index, were practically equivalent
regardless of maximum number of target lesions. Taken
together, treatment responses might be assessed best using
"mRECIST amendment in combination with 1.1 RECIST
model" rather than "mRECIST in combination with orig-
inal RECIST model (1.0 version)," especially in terms of
convenience without compromising prognostic ability. In
addition, radiologic response from all evaluation methods,
including approach of using only 1 index lesion, was
identified as the independent predictor for OS (all P <
0.001). This phenomenon means that the largest 1 index
lesion can reflect overall tumor burden as a representative to
a substantially accurate level, even in cases of multiple
tumors. Thus, only the 1 largest index lesion might be
sufficient to provide prognostic information. That is, higher
or lower concordance rates at cross-sectional level between
responses assessing a specific number of target lesions and
reference of assessing all target lesions do not necessarily
mean higher or lower prognostic significances in predicting
final survival outcomes. However, taken together, we cau-
tiously propose that evaluating at least the largest 2 target
lesions rather thanonly 1 should be recommended from the
comprehensive standpoint that response evaluation at a
cross-sectional level has been still an important endpoint in
many clinical trials.
Toour best knowledge, we first assessed prognostic values
of each radiologic parameter through an optimized statis-
tical method, C-index, in predicting survival outcomes
according to number of target lesions. To date, most inves-
tigations have dealt with intermethod concordance
between response assessment using specific number of
target lesions and using all target lesions at a cross-sectional
level (20). Second, we recruited a large number of patients
undergoing TACE. Because TACE is one of the most com-
monly used locoregional treatments, our studymay provide
more standardized, generalized results applicable to such
patients (21). In contrast, several key studies (8–10) includ-
ed subjects who were heterogeneously treated with various
treatment modalities, which may have biased interpreta-
tions of therapeutic responses and estimates of survival
outcomes. Third, to minimize false categorization in eval-
uating responses, 2 independent radiologists interpreted
radiologic responses and final classifications made by con-
sensus between themwere ultimately adopted. In our study,
the high levels of concordance between the 2 readers were
observed compared with other literatures (22–24). This is
most likely because radiologists assessed responses using
the givennumber of target lesions (i.e., up to1 target, up to 2
targets, and so on) according to the main concept of this
study. In this circumstance, interobserver variations that can
be caused by considering the remaining lesions besides
designated targets might have been prevented substantially.
And, when anyone of the 2 radiologists requested further
imaging modality for equivocal lesion, additional MRI
scans were allowed, and these data were opened to both
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radiologists. Along with providing radiologists, the detailed
information about number of target lesions to be consid-
ered for response evaluation, this process might lessen
obscurity and enhance concordance rates. Finally, we
excluded patients with a previous history ofHCC treatment.
Considering that those with insufficient responses to pre-
vious treatments or recurrent disease might have had worse
clinical outcomes, inclusion of only patients with treat-
ment-na€ve HCC might eliminate potential bias. In addi-
tion,we analyzed the best responses achieved in subsequent
TACE sessions. Among151patients classified as PRor stable
disease (using overall response by mRECIST) after the first
TACE, about one thirds (42 patients) additionally achieved
CR by means of so-called, "on-demand" protocols, and
obviously, such patients had the better OS than remaining
patients [47 (95% CI, 34.7–59.3) vs. 20.7 (95% CI, 14.5–
26.9) months; P < 0.001, respectively]. According to best
responses through "on demand" protocols among whole
population, responders had the better OS compared with
those with nonresponders [40.8 (95% CI, 35.8–45.8) vs.
13.3 (95% CI, 7.8–18.8) months; P < 0.001, respectively].
Taken together, based on our data, we validated rationales
of mRECIST guidelines, which adopted recommendation
for maximum number of target indicators suggested by
RECIST (14) and suggest that EASL criteria can provide
same efficacy without compromising prognostic ability
even when using only 2 target lesions instead of all target
lesions.
Consistent with our results, Riaz and colleagues (9) also
showed that target response assessing only 1 index lesion is
adequate for prediction of OS. In this study, differences in
prognostic value between target response and overall
responsewhenestimating the samenumberof target lesions
were statistically negligible for both EASL and mRECIST
guidelines. However, Gillmore and colleagues (3) reported
contradictory results: that target responses based on only
the changes in designated target lesions did not appropri-
ately reflect survival outcomes compared with overall
responses because target response does not consider pro-
gression outside treated areas, which is a clinically relevant
point in terms of survival outcome. Such a discrepancy
between results by Gillmore and colleagues (3) and ours
was most likely because progressive disease was relatively
infrequent in the early phase of treatment courses in our
treatment-na€ve population.
Thus study had several limitations. A potential weakness
of our study is lack of pathologic confirmation. A recent
study by Golfieri and colleagues (25) suggested that tumors
with complete lipiodol uptake arenot always translated into
"pathologic CR." However, as pathologic evaluations of
treated lesions are available only in selected cases following
resection, transplantation, or autopsy, one can suppose that
response evaluation using dynamic MRI scan would be
desirable for finer prognostification. Nevertheless, it is
evident that complete lipiodol uptake remains a substan-
tially favorable predictor, supported by many reports
(12, 20, 26–29). Furthermore, in Republic of Korea, accord-
ing to the reimbursement guidelines of the National Health
Insurance Corporation, use of dynamic MRI scanning for
response evaluation afterHCC treatment remains limited to
equivocal cases on dynamic CT scans. Second, this study
focused only on a specific population where TACE was
conducted. Because this population may not accurately
represent entire HCC population, it is subject to selection
bias. However, as TACE is the most commonly used locor-
egional therapy for HCC (30), this study may provide a
basis for future research using another population treated
with locoregional interventions or molecular-targeted
agents (30). Further work is needed to determine whether
this can also be translated to other treatment modalities.
Third, OS, the primary endpoint of this study, can be
confounded by other issues (e.g., underlying liver condi-
tion, post-TACE therapy), and thus, we attempted to min-
imize such biases by recruiting treatment-na€ve subjects
with well-preserved liver function and further analyzed
clinical data from the viewpoint of PFS, with similar results.
Fourth, radiologic evaluations are subject to inherent inter-
observer and intraobserver variation. And thus, in the
current analysis, to minimize possibility of false categoriza-
tions, 2 independent radiologists interpreted radiologic
responses and final classifications made by consensus
between them were ultimately adopted. However, radio-
logic criteria have not shown a significant correlation with
long-term outcomes in some cases (4, 31). To resolve these
potential limitations of radiologic criteria, further
researches are required to develop another method based
on both radiologic and biologic criteria for an accurate
monitoring clinical courses (32). Finally, excellent agree-
ment rates when assessing up to 2 targets might be reduced
to less than 90% in a subgroup with multiple tumors (5
tumors), as seen in the Supplementary Table S3. Although
agreement when considering up to 2 targets was still greater
than 85%, physicians should exercise caution when asses-
sing treatment responses by considering the 2 largest targets
in patients with multiple tumors (5 tumors).
In conclusion, our analysis suggests that prognostic
values for predicting OS were similar regardless of maxi-
mumnumber of target lesions. However, assessing 2 largest
target lesions rather than only 1 index lesion could be
recommended considering high concordance at a cross-
sectional level.
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